Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT SCA: Imatinib in Sickle Cell Anemia
NCT03997903Phase 2Terminated
- Sponsor
- Indiana University
- Start
- Feb 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in sickle cell disease (SCD), sponsored by Indiana University. Started Feb 2020; status: terminated.
02
Drugs
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03997903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03997903.